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Objective To describe province-wide outcomes and temporal trends of the Western Cape Province antiretroviral treatment (ART) 
programme 5 years since inception, and to demonstrate the utility of the WHO monitoring system for ART.
Methods The treatment programme started in 2001 through innovator sites. Rapid scaling-up of ART provision began early in 2004, 
located predominantly in primary-care facilities. Data on patients starting ART were prospectively captured into facility-based 
registers, from which monthly cross-sectional activity and quarterly cohort reports were aggregated. Retention in care, mortality, loss 
to follow-up and laboratory outcomes were calculated at 6-monthly durations on ART.
Findings By the end of March 2006, 16 234 patients were in care. The cohort analysis included 12 587 adults and 1709 children. 
Women accounted for 70% of adults enrolled. After 4 and 3 years on ART respectively, 72.0% of adults (95% confidence interval, 
CI: 68.0–75.6) and 81.5% (95% CI: 75.7–86.1) of children remained in care. The percentage of adults starting ART with CD4   
counts less than 50 cells/µl fell from 51.3% in 2001 to 21.5% in 2005, while mortality at 6 months fell from 12.7% to 6.6%, offset 
in part by an increase in loss to follow-up (reaching 4.7% at 6 months in 2005). Over 85% of adults tested had viral loads below 400 
copies/ml at 6-monthly durations until 4 years on ART.
Conclusion The location of care in primary-care sites in this programme was associated with good retention in care, while the 
scaling-up of ART provision was associated with reduced early mortality.
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Introduction
The national antiretroviral treatment 
(ART) programme in South Africa was 
launched in April 2004.1 However, for 
some years prior to this, demonstration 
projects had provided ART to HIV-
infected individuals with advanced 
disease through government health 
services. Several projects were located in 
the Western Cape Province which, as a 
result, is able to report on outcomes up 
to 4 years after initiation of therapy. 
The first such project began providing 
ART in Khayelitsha in May 2001,2,3 
followed by a project in Gugulethu in 
September 2002.4–6
Since inception, the clinical guide-
lines and approaches to monitoring 
used in the Western Cape Province have 
been in line with those recommended 
by WHO.7–9 The treatment setting is 
reflective of public sector health services   
in South Africa. A description of out-
comes 5 years into this provincial pro-
gramme, and after significant scaling-
up of care, has relevance to what can be 
anticipated in South Africa and other 
similar settings in the region.
This paper demonstrates that ro-
bust and useful information can be gen-
erated using a basics-first, paper-based   
monitoring system, as recommended 
by WHO.10 There are some sites in the 
province that collect clinical data elec-
tronically and enhance these data for   
cohort surveillance and research. These 
are designated as sentinel sites and ad-
dress particular clinical and epidemio-
logical questions. This takes pressure 
off the remaining sites from having to 
institute complex monitoring systems 
and ensures that in the majority of sites 
only the information essential for man-
agement and programme assessment is 
collected.
The aim of this paper is to describe 
the key clinical outcomes in the West-
ern Cape provincial ART programme, 
in patients on therapy for up to 4 years, 
and the evolution of the programme 
over a 5-year period. Secondary aims 
are to demonstrate the field utility of 
the WHO monitoring guidelines and 
the feasibility of scaling-up services 
through primary-care sites.
Programme description
The first project to routinely offer ART 
in the public sector and on a district-
wide basis in South Africa was started 
in 2001 as a partnership between the 
provincial government and Médecins 
Sans Frontières in the Cape Town 
township of Khayelitsha. At that time, 
several local clinicians had already been 
involved in ART provision through 
clinical studies and private funding and Research
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Fig. 1. Trends in enrolment of patients on ART
ART, antiretroviral therapy.
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Fig. 2. Trends in total patients on ART
ART, antiretroviral therapy.
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were able to support this and subse-
quent initiatives. These early sites can   
be considered as “innovator sites” in 
as far as they were able to grapple 
with many of the logistics of setting up 
services in anticipation of a more rapid 
scaling-up of ART services. By the time 
the national programme was launched 
in South Africa in April 2004, there 
were 16 discrete sites offering ART 
in the province, eight of which were 
in primary care. At this time there 
were 2327 patients receiving ART. By 
the end of March 2006, there were 
16 234 patients receiving ART (87% 
adults) across 43 sites, the majority   
being treated in primary-care settings 
(67% in clinics and community health 
centres, and 13% in district hospi-
tals). Enrolment increased steadily 
over this time to reach 1000 patients 
per month, with seasonal decreases 
in enrolment each December (Fig. 1 
and Fig. 2). Care was first offered as 
part of the primary-care HIV inter-
vention for children in 2002, with   
follow-up for children in this analysis 
extending to 3 years. Children were 
defined as patients starting ART under 
the age of 14 years.
Patients were considered eligible 
for ART if they had a stage IV illness 
(excluding extrapulmonary tuberculo-
sis) or a CD4 count less than 200 cells/
µl. The adult regimens used throughout 
comprised two nucleotide reverse tran-
scriptase inhibitors (NRTIs) and one 
non-nucleotide reverse transcriptase 
inhibitor (NNRTI). Initially, the NRTI 
backbone in Khayelitsha comprised 
zidovudine and lamivudine, but was   
later changed to stavudine and lami-
vudine in line with the national pro-
gramme. Paediatric regimens varied, 
with NNRTIs and protease inhibitors 680 Bulletin of the World Health Organization | September 2008, 86 (9)
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being variously used with the NRTI 
backbone.
Six-monthly CD4 counts and 
viral-load testing were provided in 
the programme, together with safety 
monitoring according to the specific 
regimens. The protocol for changing to 
second-line therapy was two consecu-
tive viral loads above 5000 copies/ml.7 
All laboratory tests were conducted 
by the National Health Laboratory 
Services. CD4 counts were performed 
using the panLeucogating method.11 
Viral loads were conducted using the 
NucliSens HIV-1 QT® assay, and later 
NucliSens EasyQ® HIV-1 assay (bio-
Mérieux, Boxtel, the Netherlands) for 
which the upper limit of detection is 
just under 400 copies/ml, hence the   
use of 400 copies/ml as the defini-
tion of suppression in all registers and 
analyses.
Data collection and analysis
The routine monitoring system
Data analysed were collected through 
the routine monitoring system. This 
system is one component of a frame-
work for the monitoring of the ART 
programme in the province (Fig. 3).   
Other components include observa-
tional cohort studies in sentinel sites, 
special studies to address priority clini-
Fig. 3. A tiered routine monitoring system for ART
ART, antiretroviral therapy.
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cal research questions, and a passive-
stimulated pharmacovigilance reporting 
system.
Patients are entered into a register 
in the order in which they start ART. 
Monthly reporting is universal across 
the sites and comprises cross-sectional 
patient and enrolment totals (Fig. 1 
and Fig. 2), the essential information 
required by managers to keep track of 
resource allocation and progress against 
targets. Quarterly cohort reports are 
also universal and are provided a quar-
ter in arrears to allow sites to complete 
the ascertainment of outcomes before   
reporting. These reports are aggre-
gated by starting quarter, as well as by 
6-monthly durations on ART, allowing 
for cohort outcomes to be reported. 
The metrics reported on quarterly in-
clude regimen (first- or second-line), 
CD4 count, viral load and outcome (i.e. 
in care, transferred out, lost to follow-
up, died).
When aggregating from the regis-
ters, the measure of advanced immune 
suppression at baseline is determined 
by the proportion of adults with a 
baseline CD4 cell count of less than 
50 cells/µl and in children a CD4 
percentage of less than 15% of total 
lymphocytes. Immunological response 
during follow-up is determined by the 
proportion of patients tested with CD4 
cell counts above 200 cells/µl or greater   
(20% in children) and virological re-
sponse by the proportion of patients 
tested with viral loads below 400   
copies/ml. All cohort analyses are lim-
ited to treatment-naive patients.
Data analysis
The monthly data are presented as 
cross-sectional monthly totals, whilst 
the quarterly data are presented as   
combined annual enrolment cohorts 
followed up until study closure. The 
monthly data cover April 2004 to March 
2006, whilst the cohort data include 
patients enrolled between May 2001 
and December 2005, followed until 
March 2006. Owing to the aggregate 
nature of the data, all data are presented 
as proportions with 95% binomial 
confidence intervals. The definition of 
“remaining in care” is patients who had 
had at least one visit in the preceding   
90 days. Correspondingly, the defini-
tion of “loss to follow-up” is patients 
who had not had a contact with the 
health services for 90 days or more. 
The small number of patients who 
transferred their care to other sites are 
excluded in both the numerator and 
the denominator in the calculation of 
the proportions remaining in care, died 
and lost to follow-up. These measures   Research
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Fig. 4. Estimates of retention in care for treatment-naive adults
ART, antiretroviral therapy.
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are limited to those patients followed 
up for at least the full duration under 
analysis. In addition, the proportion 
of patients remaining in care is further 
described as Kaplan–Meier estimates 
based on weighted survival data de-
rived from the count data. All analyses 
were performed using Stata statistical 
software version 9.0 (StataCorp. LP, 
College Station, TX, United States of 
America).
Results
Overall, 12 587 adults and 1709 chil-
dren were included in this cohort re-
port, totalling 14 296 treatment-naive 
patients. This is a near-complete repre-
sentation of all public-sector patients 
started on ART in the Western Cape 
Province by the end of 2005. Follow-
up for the oldest quarterly cohorts ex-
tends to 4 years on treatment. A further   
Table 1. Estimates of retention in care for treatment-naive adults
Duration on ART 
(months)
0 6 12 18 24 30 36 42 48
Total adults 
starting ART
12 587 8 341 4 726 2 167 852 561 328 189 80
Started before 30 Jun  
2005
31 Dec  
2004
30 Jun  
2004
31 Dec  
2003
30 Jun  
2003
31 Dec  
2002
30 Jun  
2002
31 Dec  
2001
Deaths since 
start
a,b
545 (6.7) 397 (8.8) 239 (11.6) 131 (15.8) 96 (17.6) 60 (18.9) 36 (19.7) 18 (23.1)
Lost to follow-up 
since start
b,c
340 (4.2) 286 (6.3) 148 (7.2) 27 (3.3) 18 (3.3) 13 (4.1) 5 (2.7) 1 (1.3)
Transfers out 
since start
b,d
223 (2.7) 214 (4.5) 98 (4.5) 23 (2.7) 16 (2.9) 10 (3.0) 6 (3.2) 2 (2.5)
Remaining in 
care – absolute
e,f
89.1 
(88.4–89.8)
84.9 
(83.8–85.9)
81.3 
(79.5–83.0)
80.9 
(78.1–83.6)
79.1 
(75.4–82.4)
77.0 
(72.0–81.6)
77.6 
(70.9–83.4)
75.6 
(64.6–84.7)
Remaining 
in care – 
cumulative
g,h
89.5 
(88.9–90.1)
85.3 
(84.5–86.1)
82.1 
(80.9–83.1)
80.0 
(78.5–81.4)
77.8 
(75.9–79.6)
74.8 
(72.1–77.2)
73.2 
(70.0–76.1)
72.0 
(68.0–75.6)
ART, antiretroviral therapy.
a  Deaths since start = deaths / (total - transfers out).
b  Values in parentheses are percentages.
c  Lost to follow-up since start = losses to follow-up / (total - transfers out).
d  Transfers out since start = transfers out / total.
e  Remaining in care – absolute = (total - losses to follow-up - deaths - transfers out) / (total - transfers out).
f  Values in parentheses are exact binomial confidence intervals.
g  Weighted Kaplan–Meier estimate.
h  Values in parentheses are Greenwood point-wise confidence intervals.
2.4% of patients were treatment expe-
rienced before starting ART, and were 
not included in this analysis.
The percentage of men starting 
ART has remained around 30% over 
the 5 years of enrolment in the prov-
ince, with a very slight increase over   
time. The gender breakdown of chil-
dren is not routinely recorded but 
reviews of paediatric sentinel site data 
reveal that the gender breakdown of 
children starting ART is roughly even. 
Overall, 22.7% of adults began ART 
with a CD4 count below 50 cells/µl 
while 45% of children started ART 
with a CD4 count below 15% of total 
lymphocytes.
After 4 years on ART, 76% of 
adults remained in care (Fig. 4 and 
Table 1). For each duration on ART, 
this absolute estimate was based only 
on the data for those patients who 
started that number of months previ-
ously. Using the weighted survival data, 
the Kaplan–Meier estimate of reten-
tion in care was 72.0% at 4 years on   
ART with a narrower confidence in-
terval (95% confidence interval, CI: 
68.0–75.6). A similar analysis of pae-
diatric outcomes (Fig. 5 and Table 2) 
revealed 81.5% (95% CI: 75.7–86.1) of 682 Bulletin of the World Health Organization | September 2008, 86 (9)
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Table 2. Estimates of retention in care for treatment-naive children
Duation on ART 
(months)
0 6 12 18 24 30 36
Total children 
starting ART
1 709 1 216 770 371 72 51 35
Started before 30 Jun 2005 31 Dec 2004 30 Jun 2004 31 Dec 2003 30 Jun 2003 31 Dec 2002
Deaths since start
a,b 84 (7.4) 68 (9.8) 32 (9.3) 4 (5.7) 4 (8.2) 4 (11.8)
Lost to follow-up 
since start
b,c
22 (1.9) 23 (3.3) 19 (5.5) 4 (5.7) 3 (6.1) 2 (5.9)
Transfers out since 
start
b,d
84 (6.9) 77 (10.0) 27 (7.3) 2 (2.8) 2 (3.9) 1 (2.9)
Remaining in care – 
absolute
e,f
90.6  
(88.8–92.3)
86.9  
(84.1–89.3)
85.2  
(81.0–88.8)
88.6  
(78.7–94.9)
85.7  
(72.8–94.1)
82.4  
(65.5–93.2)
Remaining in care – 
cumulative
g,h
90.9  
(89.3–92.4)
88.5  
(86.5–90.2)
84.8  
(81.9–87.2)
83.5  
(79.4–86.8)
81.5  
(75.7–86.1)
81.5  
(75.7–86.1)
ART, antiretroviral therapy.
a  Deaths since start = deaths / (total - transfers out).
b  Values in parentheses are percentages.
c  Lost to follow-up since start = losses to follow-up / (total - transfers out).
d  Transfers out since start = transfers out / total.
e  Remaining in care = (total - losses to follow-up - deaths - transfers out) / (total - transfers out).
f  Values in parentheses are exact binomial confidence intervals.
g  Weighted Kaplan–Meier estimate.
h  Values in parentheses are Greenwood point-wise confidence intervals.
Fig. 5. Estimates of retention in care for treatment-naive children
ART, antiretroviral therapy.
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children remained in care after 3 years. If 
looking only at those children who had 
been in care for the entire 3 years, the 
estimate is comparable (82.4%). In both 
adults and children starting ART, mor-
tality was highest in the first 6 months 
on therapy.
The first laboratory metric re-
ported on is the proportion of tests 
that are done when they should be 
done. This is a proxy for quality of care. 
Results were received in the cohort 
system for four out of five patients 
who should have received these tests   
(Table 3). There is currently a slight 
drop-off in the test completion propor-
tion as the duration on ART increases.
Looking at adult laboratory out-
comes, of those tested, 90.6% of adults 
achieved virological suppression by 
6 months on ART (Table 3). Although 
the proportion of patients on second-line 
regimens increases with duration on ART, 
and the data system does not distinguish 
which viral loads are done in patients on 
first-line versus those on second-line, for 
all patients combined this percentage re-
mained at 85% or above until 4 years on 
ART. At 2 years on ART, 3.7% of adults 
were on second-line, rising to 17.9% at 
4 years on ART. Combining all adult 
patients together, irrespective of the 
duration on ART, 1.3% of patients were 
reported to be on second-line regimens at   
the end of 2005. At the end of the first 
year on treatment, 74.7% of adult pa-
tients had attained a CD4 count above 
200 cells/µl or greater, rising to 86.0% 
at 2 years on ART and 95.3% at 4 years 
on ART.
The proportion of children achiev-
ing virological suppression ranged be-
tween 70% and 80% during the 3 years’ 
duration of follow-up (Table 3), while 
7.4% had been changed to second-line 
by 3 years on ART. By 2 years on ART, 
85.7% of children had achieved a CD4 
greater than 20% of lymphocytes.
As the rate of enrolment increased 
in the province (Fig. 1 and Fig. 2), the 
severity of illness in patients starting 
ART decreased, evidenced by the lower 
proportion with CD4 cell counts be-
low 50 cells/µl at ART initiation. In 
2001 and 2002, half the adult patients 
starting ART had a CD4 count below 
50 cells/µl, whereas this fell to 21.5% 
in 2005. This, coupled with the expan-
sion of the programme into different   Research
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Table 3. Laboratory outcomes in treatment-naive adults and children on ART
Duration on ART 
(months)
6 12 18 24 30 36 42 48
Adults in care and 
on ART
7 100 3 738 1 640 651 414 237 139 56
On second-line (%) 0.5 1.8 3.3 3.7 4.8 9.7 10.8 17.9
Viral loads done 5 979 3 330 1 401 573 343 171 93 44
Completion (%) 84.2 89.1 85.4 88.0 82.9 72.2 66.9 78.6
< 400 copies/ml (%) 90.6 89.0 88.1 88.3 88.0 86.0 84.9 90.9
95% CI 89.8–91.3 87.9–90.0 86.3–89.7 85.4–90.8 84.1–91.3 79.8–90.8 76.0–91.5 78.3–97.5
CD4 counts done 5 972 3 335 1 380 564 331 168 95 43
Completion (%) 84.1 89.2 84.1 86.6 80.0 70.9 68.3 76.8
≥ 200 cells/µl (%) 62.2 74.7 82.0 86.0 90.9 88.1 88.4 95.3
95% CI 60.9–63.4 73.2–76.2 79.9–84.0 82.9–88.8 87.3–93.8 82.2–92.6 80.2–94.1 84.2–99.4
Children in care and 
on ART
1 019 597 293 62 41 27 – –
On second-line (%) 0.1 0.7 2.0 4.8 4.9 7.4 – –
Viral loads done 822 531 245 53 28 20 – –
Completion (%) 80.7 88.9 83.6 85.5 68.3 74.1 – –
< 400 copies/ml (%) 72.7 72.3 74.7 77.4 78.6 75.0 – –
95% CI 69.6–75.8 68.3–76.1 68.8–80.0 63.8–87.7 59.0–91.7 50.9–91.3 – –
CD4 counts done 807 499 219 35 17 6 – –
Completion (%) 79.2 83.6 74.7 56.5 41.5 22.2 – –
> 20% lymphocytes (%) 57.5 71.5 74.9 85.7 88.2 83.3 – –
95% CI 54.0–60.9 67.4–75.5 68.6–80.5 69.7–95.2 63.6–98.5 35.9–99.6 – –
ART, antiretroviral therapy; CI, confidence interval.
communities, has seen mortality dur-
ing the first 6 months on ART almost 
halved from 12.7% to 6.6% (Fig. 6 and 
Table 4). At the same time there has 
been an increase in the proportion of 
patients lost to follow-up. For patients 
starting ART in 2005, 4.7% had been 
lost to follow-up 6 months after start-
ing ART.
Discussion
This analysis, based on routine data 
from a paper-based monitoring sys-
tem, has demonstrated good cohort 
retention at 4 and 3 years in adults and 
children respectively, combined with   
favourable immunological and viro-
logical responses to therapy.  As fewer 
patients have over time started ART 
with very low CD4 counts, so too has 
the mortality in the first 6 months of 
treatment declined.
The antiretroviral services in the 
Western Cape Province are represen-
tative of the national programme in 
South Africa, with the prior experience 
of innovator sites providing the oppor-
tunity to anticipate clinical outcomes 
and challenges that will be faced in the 
national programme.
The accumulated experience of 
these sites enabled the province to rap-
idly scale-up treatment in terms of both 
sites and patients around the time that 
the national programme became a real-
ity. It is estimated that, in the final year 
under review in this paper, half of those 
newly in need of antiretroviral therapy 
were able to access it in the province. 
The falling proportion of adult patients 
with extremely low CD4 counts at 
enrolment reflects the impact of this 
scaling-up of ART provision.
The concurrent halving in early 
mortality at 6 months on ART, which 
accompanied the improved immuno-
logical status of adults starting ART, 
suggests that the high early mortality 
that is characteristic of programmes in 
the region is in part mediated by the 
extreme disease advancement at enrol-
ment. This concurs with studies that 
have been able to stratify outcomes 
based on CD4 count categories.2,5,12,13 
Measures of the baseline CD4 count 
on enrolment may prove to be an ex-
tremely useful barometer of the extent   
to which programmes have caught up 
with the backlog in treatment in in-
stances where the need for ART cannot 
be easily assessed.
A key limitation of this analysis, 
and all analyses of aggregate data, is 
the inability to stratify outcomes by 
individual baseline measures of disease 
severity. It is not possible from this 
analysis to determine if the decline 
over time in early mortality is fully 
mediated by measured improvements 
in the baseline clinical status of patients 
starting therapy.
Increasingly,  patients  lost  to   
follow-up are outnumbering patients 
who are known to have died in devel-
oping country cohorts.14 For this reason 
we believe that retention in care is the 
most useful metric for reporting on 
programme effectiveness. Retention 
in care in this analysis at 3 and 4 years 
on ART demonstrates unequivocally 
the huge survival benefit conferred by 684 Bulletin of the World Health Organization | September 2008, 86 (9)
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Fig. 6. Temporal trends in baseline CD4 count survival and loss to follow-up at 6 
months in adults starting ART
ART, antiretroviral therapy.
95% confidence interval
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the intervention. Most of the current 
simulation models that anticipate 
either patient numbers or the costs 
associated with ART have assumed a   
median of between 6 and 7 years 
survival on ART.15 The current data at 
4 years, where 7 out of 10 adult patients 
are still in care, suggest that these esti-
mates are not overoptimistic, especially 
since many of the patients lost to care 
may well subsequently return to care, 
given the very tight definition of loss 
to follow-up.
Using 90 days without a clinical 
visit as the definition of loss to follow-
up enables programmes to rapidly   
identify changes in this parameter and 
respond appropriately. It also fits in 
very well with the quarterly cohort 
reporting ensuring that, when report-
ing one quarter in arrears, all outcomes 
can be fully ascertained. On the other 
hand, many analyses have used longer 
durations (up to 1 year) without con-
tact with the services to define loss to 
follow-up.13
Notwithstanding the definition 
used, a higher proportion of patients 
were lost to follow-up in the first 
6 months on ART in 2005 compared 
to previously. It is probable that clinic 
patient loads exceeding manageable 
numbers in some clinics are affecting 
this. It is clear that retaining patients 
in constant care will become increas-
ingly difficult as the service continues   
to expand, highlighting the importance 
of adherence promotion extending be-
yond the health services to the national 
and local media, political, social and 
religious platforms, as well as through 
community interventions. Decentral-
ization of care to more facilities, and 
the appropriate resourcing of services, 
are key to ensuring that services at indi-
vidual facilities remain of a manageable 
size and are able to appropriately retain 
patients in care.
Even though most services retained 
some capacity to actively follow up 
patients lost to care during the period 
under review, it is probable that there 
remains residual under-ascertainment 
of mortality in the latter years as loss 
to follow-up increased.16 It is further 
unknown to what extent in future the 
increased loss to follow-up will result 
in intermittent care and consequently 
increased virological resistance due to 
repeated treatment interruptions (which 
are known to be strongly associated with 
resistance).17
The slower increase over time in 
the numbers of children on ART com-
pared to adults is entirely anticipated   
and does not imply that children are 
being underprovided for. Whereas the 
number of adults newly needing ART 
increases year on year, the number 
Table 4. Temporal trends in baseline CD4 count survival and loss to follow-up at 6 months in adults starting ART
Number of adults
a 80 248 524 3981 3508
Year started on ART 2001 2002 2003 2004 2005
CD4 < 50 cells/µl
b,c 51.3 (39.8–62.6) 50.4 (44.0–56.8) 36.8 (32.7–41.1) 24.4 (23.1–25.8) 21.5 (18.8–20.6)
Mortality
c,d 12.7 (6.2–21.8) 11.7 (8.0–16.4) 9.6 (7.2–12.4) 6.0 (5.1–6.6) 6.6 (5.6–7.3)
Loss to follow-up
c,e 0.0 (0.0–4.5) 0.4 (0.0–2.2) 1.7 (0.8–3.2) 4.4 (3.7–4.9) 4.7 (3.9–5.3)
ART, antiretroviral therapy; CI, confidence interval.
a  Number starting in year and reaching 6 months of follow-up.
b  Proportion in starting cohort with CD4 counts < 50 cells/µl.
c  Values in parentheses are exact binomial confidence intervals.
d  Mortality = deaths by 6 months / (total in cohort - transfers out by 6-months).
e  Loss to follow-up = losses to follow-up by 6 months / (total in cohort - transfers out by 6 months).
of children is decreasing due to suc-
cessful implementation of a preven-
tion of mother-to-child transmission 
programme.18,19
The virological outcomes are en-
couraging and suggest that at a popu-
lation level the rates of viral rebound 
have not been alarming and are not 
undermining overall programme suc-
cess. Nevertheless, with up to one in   
five patients requiring second-line 
therapy by 5 years on ART, it is clear 
that the higher cost of second-line 
drugs will impact on total programme 
costs as programmes mature.20
There have been many lessons 
learned in implementing the WHO 
monitoring approach. This system, 
based on registers and regular cohort 
analyses, shares many attributes with 
systems that have been in use for many 
years for monitoring tuberculosis pro-
grammes. Worth noting is the value of 
differentiating sentinel from routine Research
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sites,21 liberating the majority of sites 
from onerous data-collection pro-
cedures that are designed for clinical   
research rather than for supporting rou-
tine care. It has been our experience 
that, with viral loads being available, 
managers have paid little attention 
to CD4 count outcomes in assessing 
programme performance. We have also 
found that presenting the completion 
proportions for laboratory outcomes is 
an invaluable metric over and above the 
outcomes themselves in the subset of 
patients for whom results are available. 
Finally, one of the major challenges 
emerging as models of care evolve is 
the large number of patients moving 
between facilities, who, once trans-
ferred out, are censored in the cohort 
analyses.
The ability to report on cohort 
outcomes without electronic systems 
underscores the value of implement-
ing a basics-first approach to routine 
monitoring. This does not mean that 
there is no role for the progressive and 
measured development of electronic   
systems22 but rather that the basic 
building blocks that are required for a 
paper-based system are the same mea-
sures that will make electronic systems 
a success.23
Perhaps the most important les-
son from the first 5 years of this pro-
gramme is that implementing an ART   
programme in primary-care facilities 
from the outset is feasible and can 
achieve excellent clinical results. It is 
probable that the location of care in 
community clinics is one of the key 
factors contributing to the retention of 
patients in care.24
Looking to the future, if the West-
ern Cape Province is to come close to 
the stated target of treating 80% of 
patients newly in need of therapy each 
year over the coming years, the annual 
number of patients enrolling in care   
will need to double while the total 
number of patients in care quadruples 
over a 5-year period. This will require 
even further task-shifting and expan-
sion of the service platform, given that 
enrolment is already threatened by 
capacity constraints in the existing service 
platform.25
In conclusion, this paper has dem-
onstrated excellent clinical outcomes 
5 years after the Western Cape Province 
began offering ART in the public sec-
tor, validating the decision to make this 
a primary-care intervention from the 
outset. The WHO monitoring system 
has enabled the province to keep track   
of the intervention and of the per-
formance of individual sites, while 
allowing space for more complex and 
durable solutions to be developed for 
the larger sites.  ■
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Objectif Décrire les résultats à l’échelle provinciale et les 
tendances dans le temps du programme de traitement 
antirétroviral (ART) de la province du Cap-Occidental, 5 ans après 
son lancement et démontrer l’utilité du système de surveillance   
de l’OMS pour ce traitement.
Méthodes Le programme de traitement a débuté en 2001 au 
niveau de sites « novateurs ». Un rapide passage à l’échelle 
supérieure de la délivrance du traitement a commencé début 
2004, à partir essentiellement d’établissement de soins de 
santé primaire. Des données relatives aux patients entamant 
un traitement ART ont été recueillies de manière prospective 
dans les registres des établissements de soins, ce qui a permis 
de constituer des rapports mensuels d’activité et des rapports 
trimestriels de cohorte. Les taux de rétention sous traitement 
et de mortalité, ainsi que les nombres de perdus pour le suivi 
et les résultats de laboratoire ont été calculés tous les 6 mois   
sous ART.
Résultats Fin mars 2006, 16 234 patients étaient sous 
traitement. L’analyse de cohorte a porté sur 12 587 adultes et 
1709 enfants. Les femmes représentaient 70 % des adultes 
inclus dans l’étude. Après 4 et 3 ans sous traitement ART, 
respectivement 72,0 % des adultes (intervalle de confiance à 
95 % : 68,0-75,6) et 81,5 % des enfants (IC à 95 % : 75,7-86,1)   
étaient encore sous traitement. Le pourcentage des adultes 
débutant le traitement ART avec une numération des CD4 
inférieure à 50 cellules/µl est tombé de 51,3 % en 2001 à 
21,5 % en 2005, tandis que la mortalité à 6 mois passait de   
12,7 % à 6,6 %, baisse en partie compensée par l’augmentation 
du nombre de perdus pour le suivi (atteignant 4,7 % à 6 mois 
en 2005). Plus de 85 % des adultes dépistés présentaient une 
charge virale inférieure à 400 copies/ml tous les 6 mois jusqu’à   
4 ans sous ART.
Conclusion La dispensation par ce programme des soins dans 
des sites de soins de santé primaire était associée à un taux de 
rétention satisfaisant, tandis que l’élargissement du programme   
était associé à une réduction de la mortalité précoce.
Resumen
Tratamiento antirretroviral y mortalidad temprana en Sudáfrica 
Objetivo Describir los resultados y las tendencias temporales a 
escala provincial del programa de tratamiento antirretroviral (TAR) 
de la Provincia de El Cabo Occidental a los 5 años de su puesta 
en marcha y demostrar la utilidad del sistema de vigilancia de la 
OMS para el TAR.
Métodos El programa de tratamiento dio comienzo en 2001 a 
partir de establecimientos innovadores. La rápida expansión del 
suministro de TAR comenzó a principios de 2004 y se centró 
predominantemente en los servicios de atención primaria. Los datos 
sobre los pacientes que comenzaron el TAR se reunieron de forma 686 Bulletin of the World Health Organization | September 2008, 86 (9)
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صخلم
 ايقيرفأ بونج في ةركبلما تايفولاو ةيرقەقلا تاسويرفلا تاداضبم ةجلاعلما
 جمانبرل ةينمزلا تاەاجتلااو ،ةعطاقلما ىوتسم لىع جئاتنلا حيضوت :فدەلا
 دعب بيرغلا سأرلا ةعطاقم في ةيرقەقلا تاسويرفلل ةداضلما ةيودلأاب ةجلاعلما
 صاخلا ةمظنلما ماظن ىودج زاربإو ،جمانبرلا لاخدإ نم تاونس سمخ ضيم
.ةيرقەقلا تاسويرفلا تاداضبم ةجلاعلما دصرب
 .ةثدحتسم عقاوم للاخ نم 2001 ماع في ةجلاعلما جمانرب أدب :ةقيرطلا
 ةيرقەقلا تاسويرفلا تاداضبم ةجلاعلما ميدقتب ءاقترلاا ةيرتو عيسرت أدب ماك
 ليجست متو .سياسأ لكشب ةيلولأا ةياعرلا قفارم في ،2004 ماع علطم في
 تاسويرفلا تاداضبم ةجلاعلما يقلت في اوءدب نيذلا ضىرلماب ةصاخلا تاشرؤلما
 عبر ةيبارتلأا ريراقتلا عيمجت لىع دعاس مام ،قفارلما تلاجس في ةيرقەقلا
 تحت ضىرلما ءاقبتسا تلادعم باستحا متو .يرەشلا طاشنلاو ،ةيونسلا
 لك ةيبرتخلما جئاتنلاو ،ةعباتلما نم بسرتلا وأ نادقفلاو ،تايفولاو ،ةياعرلا
.ةيرقەقلا تاسويرفلا تاداضبم ةجلاعلما نم رەشأ ةتس
 ةياعرلا تحت ضىرلما ددع نأ دجو ،2006 سرام/راذآ ةياەنب :تادوجولما
 1709و ،ًاغلاب 12 587 بيارتلأا ليلحتلا نمضت دقف .ًاضيرم 16 234 غلبي
 دعبو .ليلحتلاب ينجردلما ينغلابلا نم %70 ءاسنلا تلثم مانيب ،لافطلأا نم
 نوقلتي نم ينب ةياعرلا يقلت في رارمتسلاا ةبسن تناك تاونس عبرأ ضيم
 ةقث لصافب( %72.0 ينغلابلا نم ةيرقەقلا تاسويرفلا تاداضبم ةجلاعلما
 تناك تاونس 3 دعبو ،)75.6و 68.0 ينب ةيحجرلأا لدعم حوارت ذإ ،%95
 ةجلاعلما  نوقلتي  نيذلا  لافطلأل  ةبسنلاب  ةياعرلا  تحت  رارمتسلاا  ةبسن
 لدعم حوارت ذإ ،%95 ةـقث لصافب( %81.5 ةيرقەقلا تاسويرفلا تاداضبم
 تاداضبم ةجلاعلما اوأدب نيذلا ينغلابلا ةبسنف .)86.1و 75.7 ينب ةيحجرلأا
 ،ترلوركم لكل ةيلخ 50 نم لقأ مەيدل CD4 ددع ناكو ةيرقەقلا تاسويرفلا
 ينح في ،2005 ماع في %21.5 لىإ 2001 ماع في %51.3 نم تضفخنا
 ةجيتنلا ەذە نكلو .%6.6 لىإ %12.7 نم روەش 6 للاخ تايفولا تضفخنا
 لىإ لصتل( ةعباتلما نم اوبسرتو اودقف نم ددع ةدايز عم ًايئزج تأفاكت
 نيذلا ينغلابلا نم %85 نم ثركأف .)2005 ماع نم روەش 6 للاخ في %4.7
 لىع ترل ليم لكل ةخسن 400 نم لقأ مەيدل سويرفلا ءبع ناك مەرابتخا مت
 نم تاونس عبرأ رورم ىتحو تاسويرفلا تاداضبم ةجلاعلما نم روەش 6 ىدم
.ةيرقەقلا تاسويرفلا تاداضبم ةجلاعلما رارمتسا
 ەبحاصي جمانبرلا اذە في ةيلولأا ةياعرلا عقاوم في ةياعرلا عضو نإ :جاتنتسلاا
 ءاقترلاا نإف ەسفن تقولا فيو ،ةياعرلا في ضىرلما ءاقبتسلا ةديج تلادعم
 صلقت ەبحاصي ةيرقەقلا تاسويرفلا تاداضبم ةيئاودلا ةجلاعلما ميدقتب
.ةركبلما تايفولا
prospectiva en los registros de los centros, a partir de los cuales 
se elaboraron informes mensuales transversales de actividad e   
informes trimestrales de cohortes. La retención en el sistema de 
atención, la mortalidad, las pérdidas para el seguimiento y las 
variables de laboratorio se calcularon considerando los periodos 
de 6 meses de TAR.
Resultados Al final de marzo de 2006 se estaba tratando a 
16 234 pacientes. El análisis de cohortes abarcó a 12 587 
adultos y 1709 niños. Las mujeres representaban el 70% de 
todos los adultos estudiados. Al cabo de 4 y 3 años de TAR, 
respectivamente, el 72,0% de los adultos (intervalo de confianza 
del 95%, IC95%: 68,0–75,6) y el 81,5% (IC95%: 75,7–86,1) 
de los niños seguían atendidos. El porcentaje de adultos que 
comenzaron el TAR con recuentos de CD4 inferiores a 50 células/
µl cayó del 51,3% en 2001 al 21,5% en 2005, mientras que la 
mortalidad a 6 meses cayó del 12,7% al 6,6%, compensada en 
parte por un aumento de las pérdidas para el seguimiento (que 
alcanzó el 4,7% a los 6 meses en 2005). Más del 85% de los   
adultos analizados presentaron cargas virales inferiores a 400 
copias/ml a intervalos de 6 meses durante los 4 años de TAR.
Conclusión La ubicación de la asistencia en los centros de 
atención primaria en este programa se asoció a una buena   
retención de los pacientes, mientras que la expansión del TAR se 
asoció a una disminución de la mortalidad temprana.Research
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